Want to see LXRX full AI Analyst Report?
LXRX Stock Chart & Stats
$2.34
>-$0.01(-0.43%)
At close: 4:00 PM EDT
$2.34
>-$0.01(-0.43%)
Day’s Range― - ―
52-Week Range$1.06 - $2.68
Previous CloseN/A
Volume1.68M
Average Volume (3M)2.59M
Market Cap
$894.36M
Enterprise Value$919.00
Total Cash (Recent Filing)$190.61M
Total Debt (Recent Filing)$59.28M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Nov 11, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding444,955,930
10 Day Avg. Volume1,969,684
30 Day Avg. Volume2,593,508
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.88
Price to Sales (P/S)8.38
P/FCF Ratio-6.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.03Price Target Upside115.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$37.94M
Bulls Say, Bears Say
Bulls Say
Late-stage Clinical PipelineCompletion and over-enrollment of the SONATA-HCM Phase III trial strengthen the evidence base for Lexicon’s lead program. Greater enrollment may improve study power and supports a defined catalyst path toward top-line results and potential future commercialization.
Improved Liquidity And Balance SheetZero reported debt and higher equity improve financial flexibility while Lexicon funds late-stage research and commercialization preparation. The stronger balance sheet can extend operating capacity and reduce immediate financing pressure, although continued losses remain a constraint.
Regulatory And Partnership ProgressInternational approvals for sotagliflozin and continued licensing milestones demonstrate progress beyond internal development work. Regulatory reach and partner validation can broaden future commercialization opportunities and create milestone or royalty potential across multiple programs.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means Lexicon is not yet funding operations internally. Even with improved liquidity, ongoing cash consumption can require external financing or milestone proceeds and may limit the company’s ability to absorb setbacks.
Revenue Volatility And DeclineThe sharp revenue contraction shows that reported income remains dependent on irregular licensing recognition rather than a stable commercial base. This volatility makes financial planning harder and leaves Lexicon reliant on future approvals, partnerships, and milestone events.
Regulatory Timing UncertaintyThe delayed Zynquista NDA resubmission extends the period before a potential regulatory decision and commercial expansion. Reliance on an investigator-initiated study for submission materials adds execution complexity, which could defer product-related revenue and milestones.
Lexicon Pharmaceuticals News
LXRX FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was $1.06 and its highest was $2.68 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is $894.36M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 54 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on Aug 06, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.05 by -$0.02.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.06.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 444,955,930 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.05. Following the earnings report the stock price went down -3.673%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in LXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexicon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.03 (115.10% Upside)
$5.03 (115.10% Upside)
Blogger Sentiment
Bullish
LXRX Sentiment 67%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Decreased
By 59.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 2.6%
Last 30 Days ▼ 2.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
83.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.85%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
LXRX Company Deck
LXRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted meaningful clinical and strategic progress — notably the over-enrollment of SONATA-HCM, approaching NDA resubmission for Zynquista supported by favorable STENO1 exposure and DKA data, international regulatory activity, and milestone-driven partnership progress (LX9851) — and the company strengthened liquidity with cash rising to $190.6M and a new Hercules loan facility. Counterbalancing these positives were a steep year-over-year revenue decline (driven by lack of prior-period licensing revenue), a return to a net loss of $31.8M, increased R&D spending, and some timing uncertainty due to reliance on an investigator-led study for NDA formatting and submission. Overall, the call presented strong operational and pipeline momentum alongside expected near-term financial volatility as the company invests in late-stage programs.View all LXRX earnings summariesLXRX Stock 12 Month Forecast
Average Price Target
$5.03
▲(115.10% Upside)
Technical Analysis
Ownership Overview
61.24% Insiders
7.88% Mutual Funds
0.35% Other Institutional Investors
24.58% Public Companies and
Individual Investors